These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11067648)

  • 21. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
    Ramsberg J; Asseburg C; Henriksson M
    PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
    Jönsson B; Bebbington PE
    Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
    Woods SW
    Depress Anxiety; 2000; 12 Suppl 1():102-9. PubMed ID: 11098423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in the treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1999; 60 Suppl 14():10-5; discussion 31-5. PubMed ID: 10408420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased use of antidepressants in Canada: 1981-2000.
    Hemels ME; Koren G; Einarson TR
    Ann Pharmacother; 2002 Sep; 36(9):1375-9. PubMed ID: 12196054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions.
    Sclar DA; Skaer TL; Robison LM; Stowers JK
    Depress Anxiety; 1998; 8 Suppl 1():121-7. PubMed ID: 9809224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S; Casciano J; Kang-Cipolla L; Vodoor M; Grubin M; Clark D; Waugh W; Kelsey J; Osborn LW
    Manag Care Interface; 2000; Suppl B():19-25, 32. PubMed ID: 11183021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The costs of pharmacological treatment for major depression. The Italian Prospective Multicentre Observational Incidence-Based Study.
    Tarricone R; Fattore G; Gerzeli S; Serra G; Taddei C; Percudani M
    Pharmacoeconomics; 2000 Feb; 17(2):167-74. PubMed ID: 10947339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 May; 11(5):419-43. PubMed ID: 10168031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression.
    Kind P; Sorensen J
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():41-8. PubMed ID: 7622811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side effects, dropouts from treatment and cost consequences.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 1998 Feb; 13 Suppl 2():S1-5. PubMed ID: 9669192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies.
    Pan YJ; Knapp M; McCrone P
    J Affect Disord; 2012 Jul; 139(2):113-25. PubMed ID: 21851987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():611-21. PubMed ID: 24348057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venlafaxine:a novel antidepressant compound.
    Schweizer E; Thielen RJ; Frazer A
    Expert Opin Investig Drugs; 1997 Jan; 6(1):65-78. PubMed ID: 15989562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management challenges of chronic pain: the role of antidepressants.
    Barkin RL; Fawcett J
    Am J Ther; 2000 Jan; 7(1):31-47. PubMed ID: 11319571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The costs of depression.
    Kind P; Sorensen J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):191-5. PubMed ID: 8468441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does direct-to-consumer advertising of antidepressants lead to a net social benefit?
    Jureidini J; Mintzes B; Raven M
    Pharmacoeconomics; 2008; 26(7):557-66; discussion 567-8. PubMed ID: 18563947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.